Renal Biomarkers Market Report and Forecast 2025-2034
Description
The global renal biomarkers market was valued at USD 970.40 Million in 2024 driven by the rising incidence of kidney diseases across the globe. The market is anticipated to grow at a CAGR of 7.65% during the forecast period 2025-2034 to reach a value of USD 2028.11 Million by 2034.
Renal Biomarkers Market Overview
Biomarkers are used to perform diagnoses and prognoses of medical conditions to curate and develop effective treatments for the medical condition. Biomarkers can be lipids, proteins, microRNAs, proteomic patterns, genes, metabolites, or cells present on a urinalysis. Renal biomarkers are supposed to be used to enhance diagnosis and treatment approaches for renal diseases.
Renal Biomarkers Market Growth Drivers
Rising Research Activities Poised to Bring Therapeutic Solutions
A new study published in May 2024 revealed that researchers discovered a novel biomarker in renal cell carcinoma subtypes. The cancer type is a diverse category with more than 20 known subtypes. The discovery is poised to enhance the ability to accurately diagnose many renal cell carcinoma subtypes, including some of the rarest subtypes. The enhanced diagnostic accuracy is expected to bring personalised treatments, improving patient outcomes. The discovery may trigger more researchers and key players to conduct additional research to explore more about the biomarker, anticipating market development.
Additionally, in January 2024, a group of researchers at MIT and Yale University School of Medicine discovered a compound originally developed as a potential cancer treatment that can allegedly treat autosomal dominant polycystic kidney disease (ADPKD). The drug exploits kidney cyst cells’ vulnerability to oxidative stress, a state of imbalance between damaging free radicals and beneficial antioxidants. The promising research is expected to bring innovative diagnostic approaches and treatments to the market, driving market growth. With a growing demand for biomarkers that can enable the development of targeted therapies and personalised treatments for patients, such research initiatives aimed at improving patient outcomes will propel market value in the coming years.
Renal Biomarkers Market Trends
The market is witnessing several trends and developments to improve the current global scenario. Some of the notable trends are as follows:
Rising Prevalence of Chronic Kidney Diseases
The market growth is significantly driven by the rising prevalence of chronic kidney diseases and other conditions such as diabetes, hypertension are driving demand for effective diagnostic tools.
Advancements in Biomarker Discovery
Continuous research and development activities along with technological advancements in the domain are contributing to the discovery of new renal biomarkers offering high specificity and sensitivity. The growing number of innovations is a major market trend, further driving market value.
Increasing Awareness
The growing awareness about kidney health and increasing application of screening programs by governments and healthcare organisations are accelerating the use of renal biomarkers, propelling the market growth.
Integration of Digital Health Technologies
The market growth can be attributed to the increasing integration of renal biomarkers with digital health technologies such as electronic health records (EHRs) and wearable devices. The integration is poised to enhance the management of chronic conditions with the help of real-time monitoring, contributing to increased market demand.
Renal Biomarkers Market Segmentation
The EMR’s report titled “Global Renal Biomarkers Market Report and Forecast 2025-2034 offers a detailed analysis of the market based on the following segments:
Market Breakup by Biomarker Type:
Segmentation by Biomarker Type to Witness Substantial Growth
Based on biomarker type, the market is divided into functional biomarker, up-regulated proteins and others. These biomarkers play a critical role in diagnosing, monitoring, and managing kidney-related diseases. The segment dominance can be attributed to the continuous discoveries of new markers that allegedly enhance diagnostic accuracy and prognostic capabilities. The high reliance of healthcare professionals on the combination of biomarkers to enhance patient outcomes drives demand for personalised treatments, reducing the burden of renal diseases.
Diagnostic Labs are Expected to Dominate the Market Share by End Users
The market segment by end users includes diagnostic labs, outpatient clinics, research centers, hospitals, and others. Diagnostic labs are leading the market segment due to the rising number of biomarkers testing that takes place at diagnostic labs. It offers a wide range of biomarker tests that are used to diagnose various aspects of kidney diseases, contributing to increased market demand. Their expertise in handling complex diagnostic procedures ensures accurate results and makes them the preferred choice for renal biomarker testing, propelling market growth.
Renal Biomarkers Market Analysis by Region
Based on region, the market report covers North America, Europe, Asia-Pacific, Latin America, and Middle East and Africa. Among these, North America dominates the market share due to the high prevalence of chronic kidney diseases (CKD) in the region. The CKD prevalence is probably high due to the rising incidence of other conditions such as diabetes and hypertension requiring effective, advanced diagnostic and monitoring tools. The presence of a robust healthcare infrastructure and the presence of prominent market players boost research, development, and innovation in the region, propelling market growth.
Leading players in the Renal Biomarkers Market
The key features of the market report comprise patent analysis, grants analysis, funding and investment analysis and strategic initiatives by the leading players. The major companies in the market are as follows:
Abbott Laboratories
It is an American multinational company that develops and sells medical devices and healthcare products. The company is a global leader in diagnostic solutions and offers advanced laboratory systems and point-of-care testing products. Their diagnostics division includes immunoassays, clinical chemistry, hematology, and molecular diagnostics.
BioPorto Diagnostics AS
Copenhagen-based BioPorto is an in-vitro diagnostics company specializing in antibodies and assay development. The company is focused on developing compelling products to address unmet medical needs and tests that can help improve clinical and economic outcomes for patients, providers, and the healthcare ecosystem.
F.Hoffmann-La Roche AG
Commonly known as Roche, it is a Swiss multinational holding healthcare company operating in pharmaceuticals and diagnostics. It is the fifth-largest pharmaceutical company in the world by revenue specialising in providing treatments for cancer globally.
Siemens Healthineers AG
It is a German multinational company focused on providing innovative healthcare solutions through advanced technologies and services. The company offers a comprehensive range of diagnostic solutions, including clinical chemistry, immunoassays, hematology, and molecular diagnostics.
Thermo Fisher Scientific Inc.
It is a life science and clinical research company. Thermo Fischer develops diagnostic tests and instruments that are used in clinical and industrial settings, like immunoassays, microbiology, and molecular diagnostics.
Other key players in the market include Q² Solutions Company, BioMerieux SA, Sphingotec GmbH, Enzo Life Sciences Inc., and Randox Laboratories Ltd.
Key Questions Answered in the Renal Biomarkers Market
Renal Biomarkers Market Overview
Biomarkers are used to perform diagnoses and prognoses of medical conditions to curate and develop effective treatments for the medical condition. Biomarkers can be lipids, proteins, microRNAs, proteomic patterns, genes, metabolites, or cells present on a urinalysis. Renal biomarkers are supposed to be used to enhance diagnosis and treatment approaches for renal diseases.
Renal Biomarkers Market Growth Drivers
Rising Research Activities Poised to Bring Therapeutic Solutions
A new study published in May 2024 revealed that researchers discovered a novel biomarker in renal cell carcinoma subtypes. The cancer type is a diverse category with more than 20 known subtypes. The discovery is poised to enhance the ability to accurately diagnose many renal cell carcinoma subtypes, including some of the rarest subtypes. The enhanced diagnostic accuracy is expected to bring personalised treatments, improving patient outcomes. The discovery may trigger more researchers and key players to conduct additional research to explore more about the biomarker, anticipating market development.
Additionally, in January 2024, a group of researchers at MIT and Yale University School of Medicine discovered a compound originally developed as a potential cancer treatment that can allegedly treat autosomal dominant polycystic kidney disease (ADPKD). The drug exploits kidney cyst cells’ vulnerability to oxidative stress, a state of imbalance between damaging free radicals and beneficial antioxidants. The promising research is expected to bring innovative diagnostic approaches and treatments to the market, driving market growth. With a growing demand for biomarkers that can enable the development of targeted therapies and personalised treatments for patients, such research initiatives aimed at improving patient outcomes will propel market value in the coming years.
Renal Biomarkers Market Trends
The market is witnessing several trends and developments to improve the current global scenario. Some of the notable trends are as follows:
Rising Prevalence of Chronic Kidney Diseases
The market growth is significantly driven by the rising prevalence of chronic kidney diseases and other conditions such as diabetes, hypertension are driving demand for effective diagnostic tools.
Advancements in Biomarker Discovery
Continuous research and development activities along with technological advancements in the domain are contributing to the discovery of new renal biomarkers offering high specificity and sensitivity. The growing number of innovations is a major market trend, further driving market value.
Increasing Awareness
The growing awareness about kidney health and increasing application of screening programs by governments and healthcare organisations are accelerating the use of renal biomarkers, propelling the market growth.
Integration of Digital Health Technologies
The market growth can be attributed to the increasing integration of renal biomarkers with digital health technologies such as electronic health records (EHRs) and wearable devices. The integration is poised to enhance the management of chronic conditions with the help of real-time monitoring, contributing to increased market demand.
Renal Biomarkers Market Segmentation
The EMR’s report titled “Global Renal Biomarkers Market Report and Forecast 2025-2034 offers a detailed analysis of the market based on the following segments:
Market Breakup by Biomarker Type:
- Functional Biomarker
- Up-Regulated Proteins
- Others
- Enzyme Linked Immunosorbent Assay
- Particle Enhanced Turbidimetric Immunoassay
- Calorimetric Assay
- Chemiluminescent Enzyme Immunoassay
- Liquid Chromatography Mass Spectrometry
- Diagnosis and Disease progression Monitoring
- Research Homecare
- Others
- Diagnostic labs
- Outpatient Clinics
- Research Centers
- Hospitals
- Others
- North America
- Europe
- Asia Pacific
- Latin America
- Middle East and Africa
Segmentation by Biomarker Type to Witness Substantial Growth
Based on biomarker type, the market is divided into functional biomarker, up-regulated proteins and others. These biomarkers play a critical role in diagnosing, monitoring, and managing kidney-related diseases. The segment dominance can be attributed to the continuous discoveries of new markers that allegedly enhance diagnostic accuracy and prognostic capabilities. The high reliance of healthcare professionals on the combination of biomarkers to enhance patient outcomes drives demand for personalised treatments, reducing the burden of renal diseases.
Diagnostic Labs are Expected to Dominate the Market Share by End Users
The market segment by end users includes diagnostic labs, outpatient clinics, research centers, hospitals, and others. Diagnostic labs are leading the market segment due to the rising number of biomarkers testing that takes place at diagnostic labs. It offers a wide range of biomarker tests that are used to diagnose various aspects of kidney diseases, contributing to increased market demand. Their expertise in handling complex diagnostic procedures ensures accurate results and makes them the preferred choice for renal biomarker testing, propelling market growth.
Renal Biomarkers Market Analysis by Region
Based on region, the market report covers North America, Europe, Asia-Pacific, Latin America, and Middle East and Africa. Among these, North America dominates the market share due to the high prevalence of chronic kidney diseases (CKD) in the region. The CKD prevalence is probably high due to the rising incidence of other conditions such as diabetes and hypertension requiring effective, advanced diagnostic and monitoring tools. The presence of a robust healthcare infrastructure and the presence of prominent market players boost research, development, and innovation in the region, propelling market growth.
Leading players in the Renal Biomarkers Market
The key features of the market report comprise patent analysis, grants analysis, funding and investment analysis and strategic initiatives by the leading players. The major companies in the market are as follows:
Abbott Laboratories
It is an American multinational company that develops and sells medical devices and healthcare products. The company is a global leader in diagnostic solutions and offers advanced laboratory systems and point-of-care testing products. Their diagnostics division includes immunoassays, clinical chemistry, hematology, and molecular diagnostics.
BioPorto Diagnostics AS
Copenhagen-based BioPorto is an in-vitro diagnostics company specializing in antibodies and assay development. The company is focused on developing compelling products to address unmet medical needs and tests that can help improve clinical and economic outcomes for patients, providers, and the healthcare ecosystem.
F.Hoffmann-La Roche AG
Commonly known as Roche, it is a Swiss multinational holding healthcare company operating in pharmaceuticals and diagnostics. It is the fifth-largest pharmaceutical company in the world by revenue specialising in providing treatments for cancer globally.
Siemens Healthineers AG
It is a German multinational company focused on providing innovative healthcare solutions through advanced technologies and services. The company offers a comprehensive range of diagnostic solutions, including clinical chemistry, immunoassays, hematology, and molecular diagnostics.
Thermo Fisher Scientific Inc.
It is a life science and clinical research company. Thermo Fischer develops diagnostic tests and instruments that are used in clinical and industrial settings, like immunoassays, microbiology, and molecular diagnostics.
Other key players in the market include Q² Solutions Company, BioMerieux SA, Sphingotec GmbH, Enzo Life Sciences Inc., and Randox Laboratories Ltd.
Key Questions Answered in the Renal Biomarkers Market
- What was the global renal biomarkers market value in 2024?
- What is the global renal biomarkers market forecast outlook for 2025-2034?
- What are the regional markets covered in the EMR report?
- What is market segmentation based on biomarker type?
- How is the market segmented based on technique?
- How is the market segmented based on application?
- Who are the end-users in the market?
- What are the major factors aiding the global renal biomarkers market demand?
- How has the market performed so far and how is it anticipated to perform in the coming years?
- What are the market's major drivers, opportunities, and restraints?
- Which regional market is expected to lead the market share in the forecast period?
- Which country is expected to experience expedited growth during the forecast period?
- What are the major global renal biomarkers market trends?
- Which application is expected to dominate the market?
- Which biomarker type will dominate the market share?
- Which technique will lead the market?
- Who are the key players involved in the global renal biomarkers market?
- What is the patent landscape of the market?
- What are the current unmet needs and challenges in the market?
- How are partnerships, collaborations, mergers, and acquisitions among the key market players shaping the market dynamics?
Table of Contents
400 Pages
- 1 Preface
- 1.1 Objectives of the Study
- 1.2 Key Assumptions
- 1.3 Report Coverage – Key Segmentation and Scope
- 1.4 Research Methodology
- 2 Executive Summary
- 3 Global Renal Biomarkers Market Overview
- 3.1 Global Renal Biomarkers Market Historical Value (2018-2024)
- 3.2 Global Renal Biomarkers Market Forecast Value (2025-2034)
- 4 Vendor Positioning Analysis
- 4.1 Key Vendors
- 4.2 Prospective Leaders
- 4.3 Niche Leaders
- 4.4 Disruptors
- 5 Global Renal Biomarkers Market Landscape*
- 5.1 Global Renal Biomarkers Market: Developers Landscape
- 5.1.1 Analysis by Year of Establishment
- 5.1.2 Analysis by Company Size
- 5.1.3 Analysis by Region
- 5.2 Global Renal Biomarkers Market: Product Landscape
- 5.2.1 Analysis by Biomarker Type
- 5.2.2 Analysis by Technique
- 5.2.3 Analysis by Application
- 6 Global Renal Biomarkers Market Dynamics
- 6.1 Market Drivers and Constraints
- 6.2 SWOT Analysis
- 6.2.1 Strengths
- 6.2.2 Weaknesses
- 6.2.3 Opportunities
- 6.2.4 Threats
- 6.3 PESTEL Analysis
- 6.3.1 Political
- 6.3.2 Economic
- 6.3.3 Social
- 6.3.4 Technological
- 6.3.5 Legal
- 6.3.6 Environment
- 6.4 Porter’s Five Forces Model
- 6.4.1 Bargaining Power of Suppliers
- 6.4.2 Bargaining Power of Buyers
- 6.4.3 Threat of New Entrants
- 6.4.4 Threat of Substitutes
- 6.4.5 Degree of Rivalry
- 6.5 Key Demand Indicators
- 6.6 Key Price Indicators
- 6.7 Industry Events, Initiatives, and Trends
- 6.8 Value Chain Analysis
- 7 Global Renal Biomarkers Market Segmentation (218-2034)
- 7.1 Global Renal Biomarkers Market (2018-2034) by Biomarker Type
- 7.1.1 Market Overview
- 7.1.2 Functional Biomarker
- 7.1.3 Up-Regulated Proteins
- 7.1.4 Others
- 7.2 Global Renal Biomarkers Market (2018-2034) by Technique
- 7.2.1 Market Overview
- 7.2.2 Enzyme Linked Immunosorbent Assay
- 7.2.3 Particle Enhanced Turbidimetric Immunoassay
- 7.2.4 Calorimetric Assay
- 7.2.5 Chemiluminescent Enzyme Immunoassay
- 7.2.6 Liquid Chromatography Mass Spectrometry
- 7.3 Global Renal Biomarkers Market (2018-2034) by Application
- 7.3.1 Market Overview
- 7.3.2 Diagnosis and Disease Progression Monitoring
- 7.3.3 Research Homecare
- 7.3.4 Others
- 7.4 Global Renal Biomarkers Market (2018-2034) by End User
- 7.4.1 Market Overview
- 7.4.2 Diagnostic Labs
- 7.4.3 Outpatient Clinics
- 7.4.4 Research Centers
- 7.4.5 Hospitals
- 7.4.6 Others
- 7.5 Global Renal Biomarkers Market (2018-2034) by Region
- 7.5.1 Market Overview
- 7.5.2 North America
- 7.5.3 Europe
- 7.5.4 Asia Pacific
- 7.5.5 Latin America
- 7.5.6 Middle East and Africa
- 8 North America Renal Biomarkers Market (218-2034)
- 8.1 North America Renal Biomarkers Market (2018-2034) by Biomarker Type
- 8.1.1 Market Overview
- 8.1.2 Functional Biomarker
- 8.1.3 Up-Regulated Proteins
- 8.1.4 Others
- 8.2 North America Renal Biomarkers Market (2018-2034) by Technique
- 8.2.1 Market Overview
- 8.2.2 Enzyme Linked Immunosorbent Assay
- 8.2.3 Particle Enhanced Turbidimetric Immunoassay
- 8.2.4 Calorimetric Assay
- 8.2.5 Chemiluminescent Enzyme Immunoassay
- 8.2.6 Liquid Chromatography Mass Spectrometry
- 8.3 North America Renal Biomarkers Market (2018-2034) by Application
- 8.3.1 Market Overview
- 8.3.2 Diagnosis and Disease Progression Monitoring
- 8.3.3 Research Homecare
- 8.3.4 Others
- 8.4 North America Renal Biomarkers Market (2018-2034) by End User
- 8.4.1 Market Overview
- 8.4.2 Diagnostic Labs
- 8.4.3 Outpatient Clinics
- 8.4.4 Research Centers
- 8.4.5 Hospitals
- 8.4.6 Others
- 8.5 North America Renal Biomarkers Market (2018-2034) by Country
- 8.5.1 United States of America
- 8.5.2 Canada
- 9 Europe Renal Biomarkers Market (218-2034)
- 9.1 Europe Renal Biomarkers Market (2018-2034) by Biomarker Type
- 9.1.1 Market Overview
- 9.1.2 Functional Biomarker
- 9.1.3 Up-Regulated Proteins
- 9.1.4 Others
- 9.2 Europe Renal Biomarkers Market (2018-2034) by Technique
- 9.2.1 Market Overview
- 9.2.2 Enzyme Linked Immunosorbent Assay
- 9.2.3 Particle Enhanced Turbidimetric Immunoassay
- 9.2.4 Calorimetric Assay
- 9.2.5 Chemiluminescent Enzyme Immunoassay
- 9.2.6 Liquid Chromatography Mass Spectrometry
- 9.3 Europe Renal Biomarkers Market (2018-2034) by Application
- 9.3.1 Market Overview
- 9.3.2 Diagnosis and Disease Progression Monitoring
- 9.3.3 Research Homecare
- 9.3.4 Others
- 9.4 Europe Renal Biomarkers Market (2018-2034) by End User
- 9.4.1 Market Overview
- 9.4.2 Diagnostic Labs
- 9.4.3 Outpatient Clinics
- 9.4.4 Research Centers
- 9.4.5 Hospitals
- 9.4.6 Others
- 9.5 Europe Renal Biomarkers Market (2018-2034) by Country
- 9.5.1 United Kingdom
- 9.5.2 Germany
- 9.5.3 France
- 9.5.4 Italy
- 9.5.5 Others
- 10 Asia Pacific Renal Biomarkers Market (218-2034)
- 10.1 Asia Pacific Renal Biomarkers Market (2018-2034) by Biomarker Type
- 10.1.1 Market Overview
- 10.1.2 Functional Biomarker
- 10.1.3 Up-Regulated Proteins
- 10.1.4 Others
- 10.2 Asia Pacific Renal Biomarkers Market (2018-2034) by Technique
- 10.2.1 Market Overview
- 10.2.2 Enzyme Linked Immunosorbent Assay
- 10.2.3 Particle Enhanced Turbidimetric Immunoassay
- 10.2.4 Calorimetric Assay
- 10.2.5 Chemiluminescent Enzyme Immunoassay
- 10.2.6 Liquid Chromatography Mass Spectrometry
- 10.3 Asia Pacific Renal Biomarkers Market (2018-2034) by Application
- 10.3.1 Market Overview
- 10.3.2 Diagnosis and Disease Progression Monitoring
- 10.3.3 Research Homecare
- 10.3.4 Others
- 10.4 Asia Pacific Renal Biomarkers Market (2018-2034) by End User
- 10.4.1 Market Overview
- 10.4.2 Diagnostic Labs
- 10.4.3 Outpatient Clinics
- 10.4.4 Research Centers
- 10.4.5 Hospitals
- 10.4.6 Others
- 10.5 Asia Pacific Renal Biomarkers Market (2018-2034) by Country
- 10.5.1 China
- 10.5.2 Japan
- 10.5.3 India
- 10.5.4 ASEAN
- 10.5.5 Australia
- 10.5.6 Others
- 11 Latin America Renal Biomarkers Market (218-2034)
- 11.1 Latin America Renal Biomarkers Market (2018-2034) by Biomarker Type
- 11.1.1 Market Overview
- 11.1.2 Functional Biomarker
- 11.1.3 Up-Regulated Proteins
- 11.1.4 Others
- 11.2 Latin America Renal Biomarkers Market (2018-2034) by Technique
- 11.2.1 Market Overview
- 11.2.2 Enzyme Linked Immunosorbent Assay
- 11.2.3 Particle Enhanced Turbidimetric Immunoassay
- 11.2.4 Calorimetric Assay
- 11.2.5 Chemiluminescent Enzyme Immunoassay
- 11.2.6 Liquid Chromatography Mass Spectrometry
- 11.3 Latin America Renal Biomarkers Market (2018-2034) by Application
- 11.3.1 Market Overview
- 11.3.2 Diagnosis and Disease Progression Monitoring
- 11.3.3 Research Homecare
- 11.3.4 Others
- 11.4 Latin America Renal Biomarkers Market (2018-2034) by End User
- 11.4.1 Market Overview
- 11.4.2 Diagnostic Labs
- 11.4.3 Outpatient Clinics
- 11.4.4 Research Centers
- 11.4.5 Hospitals
- 11.4.6 Others
- 11.5 Latin America Renal Biomarkers Market (2018-2034) by Country
- 11.5.1 Brazil
- 11.5.2 Argentina
- 11.5.3 Mexico
- 11.5.4 Others
- 12 Middle East and Africa Renal Biomarkers Market (218-2034)
- 12.1 Middle East and Africa Renal Biomarkers Market (2018-2034) by Biomarker Type
- 12.1.1 Market Overview
- 12.1.2 Functional Biomarker
- 12.1.3 Up-Regulated Proteins
- 12.1.4 Others
- 12.2 Middle East and Africa Renal Biomarkers Market (2018-2034) by Technique
- 12.2.1 Market Overview
- 12.2.2 Enzyme Linked Immunosorbent Assay
- 12.2.3 Particle Enhanced Turbidimetric Immunoassay
- 12.2.4 Calorimetric Assay
- 12.2.5 Chemiluminescent Enzyme Immunoassay
- 12.2.6 Liquid Chromatography Mass Spectrometry
- 12.3 Middle East and Africa Renal Biomarkers Market (2018-2034) by Application
- 12.3.1 Market Overview
- 12.3.2 Diagnosis and Disease Progression Monitoring
- 12.3.3 Research Homecare
- 12.3.4 Others
- 12.4 Middle East and Africa Renal Biomarkers Market (2018-2034) by End User
- 12.4.1 Market Overview
- 12.4.2 Diagnostic Labs
- 12.4.3 Outpatient Clinics
- 12.4.4 Research Centers
- 12.4.5 Hospitals
- 12.4.6 Others
- 12.5 Middle East and Africa Renal Biomarkers Market (2018-2034) by Country
- 12.5.1 Saudi Arabia
- 12.5.2 United Arab Emirates
- 12.5.3 Nigeria
- 12.5.4 South Africa
- 12.5.5 Others
- 13 Regulatory Framework
- 13.1 Regulatory Overview
- 13.2 US FDA
- 13.3 EU EMA
- 13.4 INDIA CDSCO
- 13.5 JAPAN PMDA
- 13.6 Others
- 14 Patent Analysis
- 14.1 Analysis by Type of Patent
- 14.2 Analysis by Publication Year
- 14.3 Analysis by Issuing Authority
- 14.4 Analysis by Patent Age
- 14.5 Analysis by CPC Analysis
- 14.6 Analysis by Patent Valuation
- 14.7 Analysis by Key Players
- 15 Grant Analysis
- 15.1 Analysis by Year
- 15.2 Analysis by Amount Awarded
- 15.3 Analysis by Issuing Authority
- 15.4 Analysis by Grant Product
- 15.5 Analysis by Funding Institute
- 15.6 Analysis by Departments
- 15.7 Analysis by Recipient Organization
- 16 Funding and Investment Analysis
- 16.1 Analysis by Funding Instances
- 16.2 Analysis by Type of Funding
- 16.3 Analysis by Funding Amount
- 16.4 Analysis by Leading Players
- 16.5 Analysis by Leading Investors
- 16.6 Analysis by Geography
- 17 Strategic Initiatives
- 17.1 Analysis by Partnership Instances
- 17.2 Analysis by Type of Partnership
- 17.3 Analysis by Leading Players
- 17.4 Analysis by Geography
- 18 Supplier Landscape
- 18.1 Market Share Analysis, By Region (Top 5 Companies)
- 18.1.1 Market Share Analysis: Global
- 18.1.2 Market Share Analysis: North America
- 18.1.3 Market Share Analysis: Europe
- 18.1.4 Market Share Analysis: Asia Pacific
- 18.1.5 Market Share Analysis: Others
- 18.2 Abbott Laboratories
- 18.2.1 Financial Analysis
- 18.2.2 Product Portfolio
- 18.2.3 Demographic Reach and Achievements
- 18.2.4 Company News & Developments
- 18.2.5 Certifications
- 18.3 BioPorto Diagnostics AS
- 18.3.1 Financial Analysis
- 18.3.2 Product Portfolio
- 18.3.3 Demographic Reach and Achievements
- 18.3.4 Company News & Developments
- 18.3.5 Certifications
- 18.4 F.Hoffmann-La Roche AG
- 18.4.1 Financial Analysis
- 18.4.2 Product Portfolio
- 18.4.3 Demographic Reach and Achievements
- 18.4.4 Company News & Developments
- 18.4.5 Certifications
- 18.5 Thermo Fisher Scientific Inc.
- 18.5.1 Financial Analysis
- 18.5.2 Product Portfolio
- 18.5.3 Demographic Reach and Achievements
- 18.5.4 Company News & Developments
- 18.5.5 Certifications
- 18.6 Q² Solutions Company
- 18.6.1 Financial Analysis
- 18.6.2 Product Portfolio
- 18.6.3 Demographic Reach and Achievements
- 18.6.4 Company News & Developments
- 18.6.5 Certifications
- 18.7 BioMerieux SA
- 18.7.1 Financial Analysis
- 18.7.2 Product Portfolio
- 18.7.3 Demographic Reach and Achievements
- 18.7.4 Company News & Developments
- 18.7.5 Certifications
- 18.8 Sphingotec GmbH
- 18.8.1 Financial Analysis
- 18.8.2 Product Portfolio
- 18.8.3 Demographic Reach and Achievements
- 18.8.4 Company News & Developments
- 18.8.5 Certifications
- 18.9 Randox Laboratories Ltd
- 18.9.1 Financial Analysis
- 18.9.2 Product Portfolio
- 18.9.3 Demographic Reach and Achievements
- 18.9.4 Company News & Developments
- 18.9.5 Certifications
- 18.10 Siemens Healthineers AG
- 18.10.1 Financial Analysis
- 18.10.2 Product Portfolio
- 18.10.3 Demographic Reach and Achievements
- 18.10.4 Company News & Developments
- 18.10.5 Certifications
- 18.11 Enzo Life Sciences Inc.
- 18.11.1 Financial Analysis
- 18.11.2 Product Portfolio
- 18.11.3 Demographic Reach and Achievements
- 18.11.4 Company News & Developments
- 18.11.5 Certifications
- 19 Global Renal Biomarkers Market – Distribution Model (Additional Insight)
- 19.1 Overview
- 19.2 Potential Distributors
- 19.3 Key Parameters for Distribution Partner Assessment
- 20 Key Opinion Leaders (KOL) Insights (Additional Insight)
Pricing
Currency Rates
Questions or Comments?
Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.
